ArticleAntimicrobial resistance and infection control2026
Impact of beta-lactam allergy labels on antibiotic prophylaxis and surgical site infections after cesarean section; a retrospective study.
Article in Antimicrobial resistance and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReported beta-lactam allergies often lead to avoidance of first-line antibiotics and may increase surgical complications. Cesarean sections (CSs), where prophylactic antibiotics are universally administered, offer a unique setting to assess the clinical impact of these labels on outcomes. The objective of this study was to investigate the impact of beta-lactam allergy labels on surgical site infection (SSI) rates and adherence to CS prophylactic antibiotic guidelines.
methodsWe performed a retrospective cohort study of all women undergoing CS at a secondary medical center between 2018 and 2023. Women with chorioamnionitis or missing antibiotic data were excluded. Patients were grouped by the presence or absence of a beta-lactam allergy label. For each group, we assessed 30-day SSI rates and adherence to prophylaxis guidelines (drug, dose, timing). Multivariable logistic regression identified independent predictors of SSI.
resultsAmong 7,060 eligible women, 307 (4.3%) carried a beta-lactam allergy label. Not-per protocol antibiotic administered in 201/307 (65%) of labeled vs. 739/6,753 (11%) of unlabeled patients (p < 0.001), mainly due to clindamycin monotherapy (88% of inadequate regimens). SSI rates were higher among labeled patients, 20/307 (6.5%) vs. 271/6,753 (4.0%) (p = 0.031). Among all patients, SSI occurred in 266/6,733 (3.9%) receiving cefazolin-based prophylaxis, 4/64 (6.3%) with clindamycin plus gentamicin, and 21/256 (8.2%) with inadequate regimens (p = 0.003). Beta-lactam allergy labeling independently increased SSI risk (aOR 1.68, 95% CI 1.05-2.71, P = 0.031).
conclusionsBeta-lactam allergy labels were associated with an increased risk of SSI after cesarean section, due to suboptimal selection of prophylactic antibiotics. These findings underscore the importance of accurate allergy documentation and evidence-based perioperative antimicrobial stewardship to ensure optimal prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.